Residency · Residency · Neurosurgery
Stereotactic Radiosurgery: Principles and Applications
Introduction
Stereotactic radiosurgery delivers a high dose of focused radiation to a precisely defined intracranial target in a single session or a limited number of fractions, while minimizing dose to surrounding normal brain tissue. SRS is a cornerstone of modern neurosurgery, applicable to neoplastic, vascular, and functional indications. The key distinction from conventional radiotherapy is the steep dose gradient achieved through multiple converging beams, concentrating therapeutic radiation at the target while sparing adjacent structures.
Physics and Technology
Fundamental Principles
Stereotactic localization provides a rigid frame-based or frameless image-guided coordinate system for precise target definition. Dose conformality shapes the radiation isodose to match the geometry of the target. Dose falloff or selectivity ensures rapid reduction in dose at the target boundary to spare normal tissue. The radiobiology of single high-dose fractions exploits differences in the alpha/beta ratio between tumor tissue and normal brain, with tumors being more susceptible to large single doses.
Delivery Platforms
The Gamma Knife, designed by Leksell, uses 192 cobalt-60 sources focused on a single isocenter and remains the gold standard for intracranial SRS. Linear accelerator-based SRS uses modified LINACs with micro-multileaf collimators, exemplified by systems such as Novalis and BrainLab platforms. CyberKnife is a robotic LINAC with real-time image tracking that operates as a frameless system capable of both intracranial and extracranial treatments. Proton beam radiosurgery exploits the Bragg peak for superior dose conformality in select cases.
Treatment Planning
High-resolution MRI is fused with CT for target delineation. The prescription isodose is typically the 50 percent isodose line for Gamma Knife and 80 percent for LINAC-based systems. Dose selection depends on target volume, pathology, and proximity to critical structures. The maximum dose to the optic apparatus is generally kept below 8 to 10 Gy in a single fraction to avoid optic neuropathy.
Clinical Applications
Brain Metastases
Brain metastases represent the most common indication for SRS, with a growing role as an alternative to whole-brain radiation therapy. SRS is appropriate for a limited number of metastases, traditionally 1 to 4 but now expanding to 10 or more in select cases. Typical marginal doses are 18 to 24 Gy depending on size: 24 Gy for lesions under 2 centimeters and 18 Gy for those between 2 and 3 centimeters. Local control reaches 80 to 90 percent at one year. The Alliance N0574 trial demonstrated that SRS alone preserves neurocognitive function compared to SRS combined with WBRT, without a survival difference.
| Indication | Marginal Dose | Local Control / Outcome | Key Consideration |
|---|---|---|---|
| Brain metastases (<2 cm) | 24 Gy | 80-90% at 1 yr | SRS alone preserves cognition vs WBRT |
| Brain metastases (2-3 cm) | 18 Gy | 80-90% at 1 yr | Single fraction preferred |
| Vestibular schwannoma | 12-13 Gy | 90-95% at 10 yr | Hearing preservation 50-70% |
| Meningioma (Grade I) | 12-16 Gy | 90-95% at 5-10 yr | Skull base ideal |
| AVM (<3 cm) | 20-25 Gy | 70-80% obliteration at 3 yr | 2-3 yr latency; hemorrhage risk persists |
| Trigeminal neuralgia | 70-90 Gy (max dose) | 70-80% pain relief | Onset delayed weeks-months |
| Pituitary adenoma (non-functioning) | 14-18 Gy | Tumor control >90% | Hypopituitarism risk 20-30% |
Vestibular Schwannoma
SRS serves as an alternative to microsurgery for small-to-medium vestibular schwannomas under 3 centimeters or in patients unfit for surgery. The marginal dose is 12 to 13 Gy. Tumor control reaches 90 to 95 percent at 10 years. Hearing preservation is achieved in 50 to 70 percent at 5 years. The risk of facial neuropathy is less than 1 percent with modern dosimetry.
Meningioma
SRS is used for small-to-medium residual or recurrent meningiomas, particularly in skull base locations where surgical access is challenging. The marginal dose is 12 to 16 Gy for WHO Grade I tumors. Tumor control reaches 90 to 95 percent at 5 to 10 years for Grade I meningiomas. Higher-grade meningiomas benefit from fractionated stereotactic radiotherapy rather than single-fraction SRS.
Arteriovenous Malformations
SRS induces progressive endothelial proliferation and vessel obliteration over 2 to 3 years. It is optimal for AVMs under 3 centimeters, corresponding to Spetzler-Martin grades I to II, particularly in deep or eloquent locations. The marginal dose ranges from 20 to 25 Gy based on AVM volume. The obliteration rate is 70 to 80 percent at 3 years for small AVMs. During the latency period before obliteration, the annual hemorrhage risk of 2 to 4 percent persists, requiring patient counseling about this ongoing risk.
Trigeminal Neuralgia
Focused radiation of 70 to 90 Gy maximum dose is delivered to the trigeminal root entry zone. Pain relief occurs in 70 to 80 percent of patients, though onset is delayed by weeks to months. This approach carries a lower procedural risk than MVD or percutaneous procedures.
Pituitary Adenomas
SRS treats residual or recurrent adenomas after transsphenoidal surgery. The marginal dose is 14 to 18 Gy for non-functioning adenomas and 20 to 25 Gy for secreting adenomas. Biochemical remission for secreting adenomas occurs in 40 to 60 percent at 5 years. The risk of hypopituitarism is 20 to 30 percent at 5 to 10 years, necessitating long-term endocrine follow-up.
Complications and Adverse Effects
Radiation necrosis is symptomatic in 5 to 10 percent of cases and is more common with larger treatment volumes. Differentiation from tumor recurrence requires MR perfusion, MR spectroscopy, or PET imaging. Treatment options include corticosteroids, bevacizumab, and surgical resection. Perilesional edema is typically manageable with dexamethasone. Cranial neuropathies depend on proximity and dose delivered to cranial nerves. Radiation-induced tumors are exceedingly rare with a latency measured in years to decades.
Fractionated Stereotactic Radiotherapy
FSRT delivers stereotactic precision over multiple fractions, with 3 to 5 fractions for hypofractionated SRT and 25 to 30 fractions for conventional fractionation. This approach exploits normal tissue repair between fractions and is preferred for targets adjacent to the optic apparatus or brainstem and for large volumes exceeding 3 to 4 centimeters. Examples include large vestibular schwannomas, optic nerve sheath meningiomas, and skull base chordomas.
Clinical Pearls
SRS is not surgery in the traditional sense but produces equivalent or superior outcomes to open surgery for many small, deep, or surgically inaccessible lesions. For brain metastases, SRS alone without WBRT preserves neurocognitive function with equivalent survival; hippocampal avoidance WBRT is an alternative when lesion number is high. AVM radiosurgery requires thorough patient counseling about the 2 to 3 year latency period during which hemorrhage risk persists, and annual angiographic follow-up is essential until obliteration is confirmed. Radiation dose to the optic apparatus must be kept below 8 to 10 Gy in a single fraction to avoid optic neuropathy; fractionation should be employed when this constraint cannot be met.
References
- Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;46(9):797-803.
- Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401-409.
- Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg. 2005;102(Suppl):195-199.
- Pollock BE, Flickinger JC. A proposed radiosurgery-based grading system for arteriovenous malformations. J Neurosurg. 2002;96(1):79-85.